DIPEPTIDYL PEPTIDASE-IV INHIBITORY ACTIVITIES OF MEDICINAL PLANTS: TERMINALIA ARJUNA, COMMIPHORA MUKUL, GYMNEMA SYLVESTRE, MORINDA CITRIFOLIA, EMBLICA OFFICINALIS

  • Manjusha K Borde MGM Medical college
  • Rajesh Kumar Suman MGM Medical college
  • Ipseeta Ray Mohanty MGM Medical college
  • Y A Deshmukh MGM Medical college

Abstract

Objective: The present study was designed to screen the dipeptidyl peptidase-IV (DPP-IV) inhibitory ability of hydroalcoholic extracts of Terminalia
arjuna, Commiphora mukul, Gymnema sylvestre, Morinda citrifolia, and Emblica officinalis and compare their inhibitory activity with the synthetic
DPP-IV inhibitors (Sitagliptin and Vildagliptin). The aim of the study was to identifying indigenous sources of DPP-IV inhibitors for the management
of type II diabetes mellitus as alternatives to their synthetic counterparts.
Methods: The hydroalcoholic extract of T. arjuna, C. mukul, G. sylvestre, M. citrifolia, E. officinalis and synthetic DPP-IV inhibitors (Sitagliptin and
Vildagliptin) were tested in vitro for DPP-IV inhibitory activity.
Results: The DPP-IV inhibitory activity of synthetic drugs Vildagliptin was found to be 90.42±7.84% and Sitagliptin 84.67±8.21%. The DPP-IV
Inhibitory activity of T. arjuna was found to be 83.39±7.58%, C. mukul: 92.97± 8.45%, G. sylvestre: 16.98±1.69%, M. citrifolia: 24.64±2.24%, and
E. officinalis: 85.95±7.16%. C. mukul extract showed superior inhibitory activity than reference standard drugs (Sitagliptin and Vildagliptin).
Conclusion: C. mukul, T. arjuna, and E. officinalis extracts possess significant DPP-IV Inhibitory activity while G. sylvestre and M. citrifolia failed to
markedly inhibit DPP-IV enzyme.
Keywords: Type II diabetes mellitus, Dipeptidyl peptidase-IV inhibitors, Plant extracts, In vitro assay.

Author Biographies

Manjusha K Borde, MGM Medical college
Department of pharmacology
Rajesh Kumar Suman, MGM Medical college
Pharmacology
Ipseeta Ray Mohanty, MGM Medical college
Pharmacology
Y A Deshmukh, MGM Medical college
Pharmacology

References

REFERENCES
1. Drucker DJ. Enhancing incretin action for the treatment of Type 2
diabetes. Diabetes Care 2003;26(10):2929-40.
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev
1999;20(6):876-913.
3. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like
peptide-1 by human plasma in vitro yields an N-terminally truncated
peptide which is a major endogenous metabolite in vivo. J Clin
Endocrinol Metab 1995;80:952-7.
4. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase
IV from bench to bedside: An update on structural properties, functions,
and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci
2003;40:209-94.
5. Fredenrich A, Palle S, Canivet B. Dipeptidyl peptidase inhibitors:
A new step towards normoglycemia. Open Endocrinol J 2009;3:16-21.
6. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 inhibition:
Linking chemical properties to clinical safety. Curr Med Chem
2011;18(31):4753-60.
7. Nicolau Ramis J, Masmiquel Comas L. The new antidiabetic agents
in the firing line. safety reasons or witch hunt?. Endocrinol Nutr
2012;59(1):1-8.
8. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4
inhibitors and pancreatitis risk: A meta-analysis of randomized clinical
trials. Diabetes Obes Metab 2014;16(1):48-56.
9. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis,
pancreatic, and thyroid cancer with glucagon-like peptide-1-based
therapies. Gastroenterology 2011;141(1):150-6.
10. Yogisha S, Raveesha KA. Dipeptidyl peptidase IV inhibitory activity of
Mangifera indica. J Nat Prod 2010;3:76-9.
11. Bharti SK, Sharma NK, Kumar A, Krishnan S, Gupta AK, Jaiswal SK.
Dipeptidyl peptidase IV inhibitory activity of seed extracts of
Castanospermum austral and molecular docking of their alkaloids.
Topclass J Herb Med 2012;1(1):1-7.
12. Mardanyan S, Sharoyan S, Antonyan A, Zakaryan N. Dipeptidyl
peptidase IV and adenosine deaminase inhibition by 12. Armenian
planta and antidiabetic drugs. Int J Diabetes Metab 2011;19:69-74.
13. Chakrabarti R, Singh B, Narendra P, Varghese N, Vanchhawng L,
Shihabudeen MS, et al. Dipeptidyl peptidase- IV inhibitory activity of
Berberis aristata. J Nat Prod 2011;4:158-63.
14. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl
peptidase IV (DPP IV) is one of the mechanisms explaining the
hypoglycemic effect of berberine. J Enzyme Inhib Med Chem
2009;24(5):1061-6.
15. Singh AK, Jatwa R, Joshi J. Cytoprotective and dipeptidyl peptidase-IV
(DPP-IV/CD26) inhibitory roles of Ocimum sanctum and Momordica
charantia extracts. Asian J Pharm Clin Res 2014;7(1):115-20.
16. Bisht R, Bhattacharya S, Jaliwala YA. Evaluating the use of Desmodium
gangeticum as alpha glucosidase and DPPIV inhibitor for Type-II
diabetes. Am J Phytomed Clin Ther 2014;2(4):530-9.
17. Kilari EK, Mullapudi B, Moka PV, Silakabattini K, Nelli G. Inhibition
of DPP-IV activity and enhancement of GLP-1 expression by aqueous
peel extracts of Punica granatum in albino wistar rats. J Glob Trends
Pharm Sci 2014;5(2):1528-41.
18. Barve K, Bhonsle N. Commiphora mukul prevents myocardial
dysfunction in streptozotocin induced diabetic rats. Pharm Crops
2014;5(5):61-6.
19. Shirazi L, Salehi I, Moradkhani SH. Evaluation of analgesic effects of
clove extracton male offspring of surrey female miceduring lactation.
Armaghane - Danesh 2015;19(10):861-9.
20. Bellamkonda R, Rasineni K, Singareddy SR, Kasetti RB, Pasurla R,
Chippada AR, et al. Anti-hyperglycemic and antioxidant activities of
alcoholic extract of Commiphora mukul gum resin in streptozotocin
induced diabetic rats. Pathophysiology 2011;18(4):255-61.
21. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica
officinalis Gaertn.) on blood glucose and lipid profile of normal subjects
and Type 2 diabetic patients. Int J Food Sci Nutr 2011;62(6):609-16.
22. Nain P, Saini V, Sharma S, Nain J. Antidiabetic and antioxidant potential
of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced
Type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol
2012;142(1):65-71.
23. Morshed MA, Haque A, Rokeya B, Ali L. Anti-hyperglycemic
and lipid lowering effect of Terminalia arjuna bark extract on
streptozotocin indiced Type 2 diabetic model rats. Int J Pharm Pharm
Sci 2011;3(4):450-4.
24. Parveen K, Khan R, Siddiqui WA. Antidiabetic effects afforded by
Terminalia arjuna in high fat-fed and streptozotocin - induced Type 2
diabetic rats. Int J Diabetes Metab 2011;19:23-33
Statistics
3763 Views | 836 Downloads
How to Cite
Borde, M. K., R. K. Suman, I. R. Mohanty, and Y. A. Deshmukh. “DIPEPTIDYL PEPTIDASE-IV INHIBITORY ACTIVITIES OF MEDICINAL PLANTS: TERMINALIA ARJUNA, COMMIPHORA MUKUL, GYMNEMA SYLVESTRE, MORINDA CITRIFOLIA, EMBLICA OFFICINALIS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 3, May 2016, pp. 180-2, https://innovareacademics.in/journals/index.php/ajpcr/article/view/10894.
Section
Original Article(s)